Drug Pricing Policies

-
Speaker : MOHAMMAD ELNADI
-
When : Friday, September 12, 2025
-
Time : 01 : 00 PM EST
-
Add To Calendar
Refer a Friend
Mohammad is a highly accomplished pharmaceutical
professional with over 20 years of experience in the pharmaceutical
industry, specializing in business development, regulatory affairs,
supply chain management, and international training. As a co-founder of
the Arab Pharma Experts Association (APEA), Mohammad has established
himself as a trusted expert in the field, combining his deep regulatory
knowledge with strong business acumen to drive success in both local and
international markets.
Mohammad began his
career after earning a bachelor’s degree in Pharmaceutical Science from
the University of Cairo in 2005. He quickly gained hands-on experience
in research and development (R&D) and production of pharmaceutical
dosage forms, as well as in coordinating contract manufacturing
activities. His passion for continuous learning led him to pursue a
postgraduate certificate in management from the American University in
Cairo (AUC), where he honed his skills in marketing, project management,
finance, and organizational behavior.
Over
the years, Mohammad has held several senior management roles, including
Business Development Senior Officer, Supply Chain Manager, and Product
development project manager at Elrazy Pharmaceuticals Co. In these
positions, he successfully led market access projects, negotiated deals
with overseas agents, and established supply chain strategies that
aligned with the company’s overall goals. His efforts have enabled
Elrazy Pharmaceuticals to expand its presence in key markets across
Africa, ASEAN, and the GCC regions.
In
addition to his corporate roles, Mohammad has served as an independent
pharmaceutical consultant and trainer, working with organizations such
as IPI Academy in London and Pharmastate Academy in Delhi. He has
delivered a wide range of training courses on topics such as Regulatory
landscape, regulatory project management, supply chain optimization, and
risk management. His expertise has benefited professionals from leading
pharmaceutical companies across Egypt, UAE, KSA, Sudan, Spain,
Portugal, Sweden & beyond.
Mohammad’s
extensive experience also includes roles as Managing Director of REYADA
PRO for pharmaceutical services and consultancy, where he provided
strategic guidance to clients, and as Regulatory Business Development
Manager at REG EXPERTS, where he helped companies navigate complex
regulatory landscapes. His ability to bridge the gap between regulatory
compliance and business strategy has made him a sought-after expert in
the industry.
As an international trainer,
Mohammad has conducted numerous online and offline courses, sharing his
knowledge with professionals from diverse geographical regions. His
training programs cover critical areas such as MENA region guidelines
for drug registration, pharmaceutical supply chain management, and
product development. His practical approach and real-world insights have
earned him a reputation as a dynamic and engaging trainer.
Mohammad’s
educational background is complemented by a wide range of professional
certifications, including Lean Green Belt, QMS Lead Auditor ISO 9001,
and a Data Analytics Nanodegree from Udacity. He is also a certified
business analyst and has completed advanced courses in strategic
marketing, communication skills, and problem-solving.
With
a proven track record of driving cost efficiency, regulatory
compliance, and market expansion, Mohammad continues to make significant
contributions to the pharmaceutical industry. His unique blend of
regulatory expertise, business development skills, and training
capabilities positions him as a key player in shaping the future of
pharmaceutical manufacturing and supply chain management.
The price of medicines is one of the factors that can limit the affordability of medicines to the population.
So there are many drug pricing policies that could be implemented by the regulatory authorities based on the level of control they intend to implement on drug prices in the national market to assure that drugs are available in the market at fair prices.
The national regulatory authority may follow one policy or combination of more than one of pricing policies to assure the fair pricing of medicines registered in their market.
So the company should be aware of those policies and what policy the intended market regulatory authority is applying, so it can predict the range of prices that its product may acquire.
In this webinar, we will discuss the different policies applied by the regulatory authorities and the power of negotiation that the company may have against the authority. Also, we will discuss the different terminologies in drug pricing to be aware of each item in the pricing structure.
Areas Covered
- Helicopter view on international pricing of drugs
- Factors considered by the payers and regulatory authorities when deciding on drug prices
- Different types of pricing systems
- National pricing policies and systems in different countries for innovative & generic products
- Different pricing techniques and the differences between them
- Drug pricing terms (Ex-factory, FOB, CIF, retail…etc)
Who Should Attend
- Top management in pharmaceutical companies
- Regulatory affairs professionals
- Business improvement delegates
- Market access delegates
- Export professionals
- Anyone involved in the drug pricing process
Why Should You Attend
- Understand the different terminologies used in drug pricing
- Understand the different policies in drug pricing
- Be aware of the current rules of drug pricing in different countries
- Be aware of factors affecting the dug pricing
Topic Background
Access to medicines is a human right, and some countries incorporate it in their national constitution.
The price of medicines is one of the factors that can limit the affordability of medicines to the population.
There are many drug pricing policies that could be implemented by the regulatory authorities based on the level of control they intend to implement on drug prices in the national market.
The national regulatory authority may follow one policy or combination of more than one of pricing policies to assure the fair pricing of medicines registered in their market.
By the end, drug pricing, as it is called by many experts, “The moment of truth” as it is the moment where you, as a pharmaceutical company, know if you can have the return on investment you invested in developing the new medicines or not.
-
$199.00
-
